The University of Osaka · 의학
모토하이드 우에무라 교수의 연구실은 전이성 전립선암, 특히 카우스미아 저항성 전립선암(CRPC)의 발병 기전과 새로운 치료 타겟을 규명하는 데 초점을 맞추고 있습니다. 유전자 발현 분석과 단백질체 분석을 통해 종양 미세환경에서의 호르몬 대사 및 엑소좀 기반 신호 전달 메커니즘을 규명하고 있으며, 이는 암의 전이 및 치료 저항성에 기여하는 핵심 요소로 작용합니다. 특히, 혈청에서 추출한 엑소좀 단백질 분석을 통해 새로운 바이오마커와 치료 타겟을 도출하고자 하는 연구가 핵심입니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Prostate cancer often relapses during androgen-depletion therapy, even under conditions in which a drastic reduction of circulating androgens is observed. There is some evidence that androgens remain present in the tissues of hormone-refractory prostate cancers (HRPC), and enzymes involved in the androgen and steroid metabolic pathway are likely to be active in HRPC cells. We previously carried out a genome-wide gene expression profile analysis of clinical HRPC cells by means of cDNA microarrays
The phase 3 JAVELIN Renal 101 trial of avelumab + axitinib vs sunitinib in patients with treatment-naive advanced renal cell carcinoma (RCC) demonstrated significantly improved progression-free survival (PFS) and higher objective response rate (ORR) with the combination vs sunitinib. Japanese patients enrolled in the study (N = 67) were randomized to receive avelumab + axitinib (N = 33) or sunitinib (N = 34); 67% vs 59% had PD-L1+ tumors (≥1% of immune cells) and 6%/64%/27% vs 6%/82%/12% had Int
Prostate cancer is the second leading cause of cancer death in men in the United States. Several novel therapeutic agents have been developed for castration-resistant prostate cancer (CRPC), but the prognosis for patients with CRPC remains poor. The identification of novel therapeutic targets for CRPC is an urgent issue. Exosomes are small vesicles secreted by a variety of cells, and exosomes derived from cancer cells have been reported to circulate in the patient's bodily fluids, promoting meta
